Clinical trial
Study of Combivir for Patients With Primary Biliary Cirrhosis
NCT00490620 · University of Alberta, Other · Completed
Key facts
| NCT number | NCT00490620 |
|---|---|
| Title | Study of Combivir for Patients With Primary Biliary Cirrhosis |
| Official title | Randomized Controlled Pilot Study of Combivir for Patients With Primary Biliary Cirrhosis |
| Lead sponsor | University of Alberta, Other |
| Collaborators | GlaxoSmithKline Industry Axcan Pharma |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Primary Biliary Cirrhosis |
| Intervention type | Drug |
| Interventions | Combination antiviral therapy, Placebo |
| Enrollment | 59 |
| Start date | Jan 1, 2004 |
| Completion | Apr 1, 2007 |
| First posted | Jun 25, 2007 |
| Last update posted | Nov 1, 2007 |
| Countries | Canada, United Kingdom, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: